Key facts
- SparingVision’s last known valuation is $158.9M (Jun 2025).
- It has raised $205.0M; the latest was Later Stage VC ($40.3M) in Jun 2025.
- Notable investors include Bpifrance, European Innovation Council, European Commission, La French Tech, UPMC Enterprises — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for SparingVision
- ·The full record, as it builds
Funding rounds
No funding rounds for SparingVision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SparingVision
Developer of a medical therapy designed to treat Retinitis Pigmentosa which is part of Inherited Retinal Diseases. The company's offerings include a drug candidate to treat retinitis pigmentosa, the most frequent inherited retinal degeneration that can progress to blindness and affects many patients worldwide, enabling doctors to help patients recover from retinal diseases.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2016
- Employees
- 49
- Website
- sparingvision.com/
- Ownership
- Privately Held (backing)
SparingVision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SparingVision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SparingVision in its N-PORT filings yet. We sweep new filings monthly.